Close Menu

mergers & acquisitions

The reduction in workforce is "intended to eliminate redundancies in the company's workforce as a result of the merger and to streamline the company's operations following the merger," Accelrys said in an SEC filing.

This is the third time in the past two weeks that Symyx has declined Certara's bid, saying it does not constitute a superior offer to Accelrys' offer to buy the firm.

Symyx also disclosed in filings with the US Securities and Exchange Commission this week that it has entered a memorandum of understanding to settle a class action suit filed by several of its shareholders regarding its impending merger agreement with Accelrys.

Symyx's board has rejected Certara's bid for the second time this week and has urged shareholders to vote in favor of a deal with Accelrys.

ExonHit said that it anticipates a lack of quorum to vote on the acquisition, which last week hit a snag on the news that Medicare may drop RedPath's pancreatic cancer test.

Symyx's board has decided that Certara's recently lowered bid is not superior to the initial agreement Symyx signed to merge with Accelrys.

The new offer, worth around $200 million, comes as Symyx prepares to finalize its previously disclosed merger with Accelrys, which values Symyx at $178 million.

The firms' merger combines technologies for pharmacogenomic testing and gene-interaction informatics.

The $7.2B deal was approved by 98 percent of shareholders who voted.

The firm has decided to focus on growing its molecular diagnostics services business rather than continuing to pursue a deal with a partner.

Pages

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.